Citat:
Dags att faktakolla ordsallads producenten nr 1 på FB;
Citat:
No, neither Robert F. Kennedy Jr. (RFK Jr.) nor Donald Trump has promised to reduce drug prices by 1400% (or even 1500%). This figure appears to stem from a misinterpretation or exaggeration of Trump's broader campaign and policy rhetoric on lowering prescription drug costs, where he has repeatedly emphasized massive reductions tied to aligning U.S. prices with those in other countries (often 3–5 times lower abroad, per government data). However, the specific 1400% claim is not a direct promise from either figure and has been debunked as mathematically impossible and unsubstantiated in fact-checks. Below, I'll break down the relevant promises, context, and evidence.Trump's Promises on Drug PricesTrump has made aggressive pledges to cut drug prices since his 2016 campaign, framing it as ending "global freeloading" where Americans subsidize lower prices abroad. In his second term (starting January 2025), he has acted on this via executive orders, but the reductions discussed are in the range of 30–90%, not 1400%.Key Promises and Actions
uring the 2024 campaign, Trump promised to "bring back" his first-term "most-favored-nation" (MFN) policy, which would tie Medicare drug prices to the lowest rates in other developed countries. He described this as delivering "the best prices in the world" and slashing costs dramatically, citing examples like U.S. prices being "3 times higher" than in comparable nations.
On May 12, 2025, Trump signed an executive order directing pharmaceutical companies to lower U.S. prices to match the lowest "most-favored-nation" rates abroad, or face penalties like mandatory cuts of 50–89%. This was flanked by RFK Jr. (then HHS Secretary nominee, confirmed later). Trump stated it would cut prices "almost immediately" and by "up to 90%."
In a July 31, 2025, White House fact sheet, the administration outlined letters to drugmakers demanding MFN pricing, noting U.S. brand-name drug prices are "more than three times" those in OECD countries. This builds on Trump's first-term efforts, which were partially rescinded under Biden.
On August 25, 2025, Trump reiterated plans for "reducing drug prices by 1400%-1500%," but this was in the context of hyperbolic rhetoric about overall savings, not a literal policy target. Fact-checks confirm this is not possible: A 100% reduction would make drugs free, and anything beyond implies negative pricing (e.g., rebates exceeding the original cost), which no policy proposes. GROK
uring the 2024 campaign, Trump promised to "bring back" his first-term "most-favored-nation" (MFN) policy, which would tie Medicare drug prices to the lowest rates in other developed countries. He described this as delivering "the best prices in the world" and slashing costs dramatically, citing examples like U.S. prices being "3 times higher" than in comparable nations.On May 12, 2025, Trump signed an executive order directing pharmaceutical companies to lower U.S. prices to match the lowest "most-favored-nation" rates abroad, or face penalties like mandatory cuts of 50–89%. This was flanked by RFK Jr. (then HHS Secretary nominee, confirmed later). Trump stated it would cut prices "almost immediately" and by "up to 90%."
In a July 31, 2025, White House fact sheet, the administration outlined letters to drugmakers demanding MFN pricing, noting U.S. brand-name drug prices are "more than three times" those in OECD countries. This builds on Trump's first-term efforts, which were partially rescinded under Biden.
On August 25, 2025, Trump reiterated plans for "reducing drug prices by 1400%-1500%," but this was in the context of hyperbolic rhetoric about overall savings, not a literal policy target. Fact-checks confirm this is not possible: A 100% reduction would make drugs free, and anything beyond implies negative pricing (e.g., rebates exceeding the original cost), which no policy proposes. GROK
